Herrero MJ¹, Botella R², Algás R³, Marco FM⁴ and Aliño SF¹

¹Gene Therapy Group, Dpto. Farmacologia, Fac. Medicina, Univ.Valencia, Valencia, España. ²Servicio Dermatologia, Instituto Valenciano Oncologia,Valencia, España. ³Servicio Radioterapia, Hospital Clínico Universitario,Valencia, España. ⁴ASAC Pharmaceutical International, Alicante, España.

Abstract

Cancer vaccines have always been in the scope of gene therapy research. One of the most successful approaches has been working with genetically modified tumor cells. However, to become a clinical reality, tumor cells must suffer a long and risky process from the extraction from the patient to the reimplantation as a vaccine. In this work, we explain our group’s approach to reduce the cell number required to achieve an immune response against a melanoma murine model, employing bead-selected B16 tumor cells expressing GM-CSF and B7.2.